lobbying_activities: 1808094

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1808094	9a5dd130-2e57-44c3-a99d-43de978a5cf9	Q1	APOTEX CORP.	310973	APOTEX CORP.	2016	first_quarter	PHA	H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S. 2615, the Increasing Competition in Pharmaceuticals Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs; Federal policy relating to requirements for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 131, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity period; Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs; and Federal policy relating to generic drug prices.	HOUSE OF REPRESENTATIVES,SENATE		130000	0	0	2016-04-14T16:41:20.290000-04:00